Dengue Vaccine (QDENGA (TAK-003))
Why in News?
The dengue vaccine QDENGA (TAK-003) is in the news because the Drug Controller General of India (DCGI) has officially granted market authorization to the vaccine, making it India's first-ever approved dengue vaccine.
Vaccine Profile & Composition
- Developer: Created by the Japanese multinational pharmaceutical company, Takeda Biopharmaceuticals.
- Vaccine Type: It is a live-attenuated (weakened) tetravalent vaccine.
- The Genetic Backbone: It uses a live-attenuated Dengue Serotype 2 (DENV-2) virus as its genetic framework. The surface proteins of serotypes 1, 3, and 4 are engineered into this backbone to trigger a defensive response against all four strains.
- Approved Age Group: Cleared for use in individuals aged 4 to 60 years.
- Serostatus Independent: It can be safely given to both dengue-naive individuals (those who have never had dengue) and seropositive individuals (those who have survived a past infection).
- Schedule: It is a two-dose regimen administered subcutaneously (under the skin).
- Interval: The second dose must be taken exactly three months after the first.
- Symptomatic Prevention: Clinical trials demonstrate 80.2% efficacy against virologically confirmed dengue 12 months post-vaccination.
- Hospitalisation Reduction: Shows 90.4% efficacy in preventing severe, hospital-grade dengue at 18 months, with protection sustained up to 4.5 to 7 years.
- Strain Discrepancy Note: While highly effective across all four strains in previously exposed individuals, it shows stronger efficacy against DENV-1 and DENV-2 in dengue-naive individuals.
- Global Footprint: Already approved and distributed across 43 countries, including the UK, EU, Brazil, and Indonesia.
- WHO Status: It holds World Health Organization (WHO) prequalification, authorizing its procurement by global agencies like UNICEF.
- Make in India Tie-up: Takeda partnered with Hyderabad-based Biological E to scale production up to 50 million doses annually to meet global demands.
- Not Transmission-Blocking: QDENGA is a disease-modifying vaccine. It drastically reduces medical severity and hospitalization but does not completely stop mosquito transmission or prevent light infections.
- Mosquito Control remains Mandatory: Public health bodies stress that the vaccine must complement—not replace—vector management, stagnant water clearing, and mosquito repellent use.
